Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
19
06
2021
accepted:
13
08
2021
pubmed:
9
9
2021
medline:
27
4
2022
entrez:
8
9
2021
Statut:
ppublish
Résumé
Alcohol-associated liver disease (ALD) is emerging worldwide as the leading cause of liver-related morbidity, mortality, and indication for liver transplantation. The ALD Special Interest Group and the Clinical Research Committee at the digital American Association for the Study of Liver Diseases meeting in November 2020 held the scientific sessions to identify clinical unmet needs in ALD, and addressing these needs using clinical research methodologies. Of several research methodologies, the sessions were focused on (a) studying disease burden of ALD using large administrative databases, (b) developing biomarkers for noninvasive diagnosis of alcohol-associated hepatitis (AH) and estimation of disease prognosis, (c) identifying therapeutic targets for ALD and AH, (d) deriving accurate models to predict prognosis or posttransplant alcohol relapse as a basis for developing treatment algorithm and a uniform protocol on patient-selection criteria for liver transplantation, and (e) examining qualitative research methodologies in studying the barriers to implementation of multidisciplinary integrated care model by hepatology and addiction teams for the management of dual pathology of liver disease and of alcohol use disorder. Prospective multicenter studies are required to address many of these clinical unmet needs. Further, multidisciplinary care models are needed to improve long-term outcomes in patients with ALD.
Identifiants
pubmed: 34496071
doi: 10.1002/hep.32143
pmc: PMC9235468
mid: NIHMS1813051
pii: 01515467-202204000-00022
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1026-1037Subventions
Organisme : NIAAA NIH HHS
ID : U01 AA026977
Pays : United States
Informations de copyright
© 2021 American Association for the Study of Liver Diseases.
Références
GBD 2017 Cirrhosis Collaborators . The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–66.
Shah VH. Alcoholic liver disease: the buzz may be gone, but the hangover remains. Hepatology. 2010;51:1483–4.
Szabo G, Kamath PS, Shah VH, Thursz M, Mathurin P, Addolorato G, et al. Alcohol‐related liver disease: areas of consensus, unmet needs and opportunities for further study. Hepatology. 2019;69:2271–83.
Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019;23:39–50.
Asrani SK, Mellinger J, Arab JP, Shah VH. Reducing the global burden of alcohol‐associated liver disease: a blueprint for action. Hepatology. 2021;73:2039–50.
Singal AK, Arora S, Wong RJ, Satapathy SK, Shah VH, Kuo YF, et al. Increasing burden of acute‐on‐chronic liver failure among alcohol‐associated liver disease in the young population in the United States. Am J Gastroenterol. 2020;115:88–95.
Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817.
Asrani SK, Trotter J, Lake J, Ahmed A, Bonagura A, Cameron A, et al. Meeting Report: The Dallas Consensus Conference on liver transplantation for alcohol associated hepatitis. Liver Transpl. 2020;26:127–40.
Shah ND, Ventura‐Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, et al. Alcohol‐related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol. 2019;17:2320–9.e2312.
Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872–82.
Guirguis J, Chhatwal J, Dasarathy J, Rivas J, McMichael D, Nagy LE, et al. Clinical impact of alcohol‐related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res. 2015;39:2085–94.
Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020;115:96–104.
Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001–2016. JAMA. 2019;321:1723–25.
Mellinger JL, Fernandez A, Shedden K, Winder GS, Fontana RJ, Volk ML, et al. Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol‐associated cirrhosis. Alcohol Clin Exp Res. 2019;43:334–41.
Rogal S, Youk A, Zhang H, Gellad WF, Fine MJ, Good CB, et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology. 2020;71:2080–92.
Lee BP, Im GY, Rice JP, Weinberg E, Hsu C, Fix OK, et al. Underestimation of liver transplantation for alcoholic hepatitis in the national transplant database. Liver Transpl. 2019;25:706–11.
Tapper EB, Korovaichuk S, Baki J, Williams S, Nikirk S, Waljee AK, et al. Identifying patients with hepatic encephalopathy using administrative data in the ICD‐10 era. Clin Gastroenterol Hepatol. 2021;19:604–6.e601.
Kirpich IA, McClain CJ, Vatsalya V, Schwandt M, Phillips M, Falkner KC, et al. Liver injury and endotoxemia in male and female alcohol‐dependent individuals admitted to an alcohol treatment program. Alcohol Clin Exp Res. 2017;41:747–57.
Louvet A, Naveau S, Abdelnour M, Ramond M‐J, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–54.
Singal AK, Salameh H, Singal A, Jampana SC, Freeman DH, Anderson KE, et al. Management practices of hepatitis C virus infected alcoholic hepatitis patients: a survey of physicians. World J Gastrointest Pharmacol Ther. 2013;4:16–22.
Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619–28.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016;150:785–90.
Liangpunsakul S, Puri P, Shah VH, Kamath P, Sanyal A, Urban T, et al. Effects of age, sex, body weight, and quantity of alcohol consumption on occurrence and severity of alcoholic hepatitis. Clin Gastroenterol Hepatol. 2016;14:1831–8.e1833.
Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, et al. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis. Clin Gastroenterol Hepatol. 2020;18:2046–54.
Bissonnette J, Altamirano J, Devue C, Roux O, Payancé A, Lebrec D, et al. A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology. 2017;66:555–63.
Atkinson SR, Grove JI, Liebig S, Astbury S, Vergis N, Goldin R, et al. In severe alcoholic hepatitis, serum keratin‐18 fragments are diagnostic, prognostic, and theragnostic biomarkers. Am J Gastroenterol. 2020;115:1857–68.
He L, Vatsalya V, Ma X, Zhang J, Yin X, Kim S, et al. Metabolic profiling of bile acids in the urine of patients with alcohol‐associated liver disease. Hepatol Commun. 2021;5:798–811.
Yang Z, Kusumanchi P, Ross RA, Heathers L, Chandler K, Oshodi A, et al. Serum metabolomic profiling identifies key metabolic signatures associated with pathogenesis of alcoholic liver disease in humans. Hepatol Commun. 2019;3:542–57.
Byrnes SA, Weigl BH. Selecting analytical biomarkers for diagnostic applications: a first principles approach. Expert Rev Mol Diagn. 2018;18:19–26.
Peeraphatdit T.B., Kamath PS, Karpyak VM, Davis B, Desai V, Liangpunsakul S, et al. Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2020;18:477–85.e475.
Halter CC, Dresen S, Auwaerter V, Wurst FM, Weinmann W. Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. Int J Legal Med. 2008;122:123–8.
Helander A, Peter O, Zheng Y. Monitoring of the alcohol biomarkers PEth, CDT and EtG/EtS in an outpatient treatment setting. Alcohol Alcohol. 2012;47:552–7.
Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta‐analysis. Gastroenterology. 2015;149:958–70.e912.
Mathurin P, Thursz M. Endpoints and patient stratification in clinical trials for alcoholic hepatitis. J Hepatol. 2019;70:314–8.
Seitz HK, Bataller R, Cortez‐Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:1–22.
Szabo G, Momen‐Heravi F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2017;14:455–66.
Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542–52.
Petrasek J, Iracheta‐Vellve A, Saha B, Satishchandran A, Kodys K, Fitzgerald KA, et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross‐talk between hepatocytes and immune cells in alcoholic liver disease. J Leukoc Biol. 2015;98:249–56.
Szabo G. Gut–liver axis in alcoholic liver disease. Gastroenterology. 2015;148:30–6.
Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, et al. Recovery of ethanol‐induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut. 2018;67:891–901.
Lang S, Duan YI, Liu J, Torralba MG, Kuelbs C, Ventura‐Cots M, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020;71:522–38.
Philips CA, Pande A, Shasthry SM, Jamwal KD, Khillan V, Chandel SS, et al. Healthy donor fecal microbiota transplantation in steroid‐ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017;15:600–2.
Bajaj JS, Gavis EA, Fagan A, Wade JB, Thacker LR, Fuchs M, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder. Hepatology. 2021;73:1688–700.
Tilg H, Moschen AR, Szabo G. Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016;64:955–65.
Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL‐1 receptor antagonist ameliorates inflammasome‐dependent alcoholic steatohepatitis in mice. J Clin Investig. 2012;122:3476–89.
Florentino RM, Fraunhoffer NA, Morita K, Takeishi K, Ostrowska A, Achreja A, et al. Cellular location of HNF4α is linked with terminal liver failure in humans. Hepatol Commun. 2020;4:859–75.
Machado MV, Diehl AM. Hedgehog signalling in liver pathophysiology. J Hepatol. 2018;68:550–62.
Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL‐22‐IL‐22R1 system. Nat Rev Drug Discov. 2014;13:21–38.
Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, et al. An open‐label, dose‐escalation study to assess the safety and efficacy of IL‐22 agonist F‐652 in patients with alcohol‐associated hepatitis. Hepatology. 2020;72:441–53.
Spahr L, Lambert JF, Rubbia‐Brandt L, Chalandon Y, Frossard JL, Giostra E, et al. Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008;48:221–9.
Marot A, Singal AK, Moreno C, Deltenre P. Granulocyte colony‐stimulating factor for alcoholic hepatitis: a systematic review and meta‐analysis of randomised controlled trials. JHEP Rep. 2020;2:100139.
Wang Y, Lin W, Brown JE, Chen L, Pandak WM, Hylemon PB, et al. 25‐Hydroxycholesterol 3‐sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes. J Lipid Res. 2021;62:100063.
McClain CJ, Vatsalya V, Rex R, Hassanein TI, Stein LL, Flamm SL, et al. DUR‐928 therapy for acute alcoholic hepatitis: a pilot study. Hepatology. 2019;70:1483–1484 A.
Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O’Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology. 2015;149:398–406.e398; quiz e316–397.
Volk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med. 2011;155:503–8.
Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–800.
Foster PF, Fabrega F, Karademir S, Sankary HN, Mital D, Williams JW. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology. 1997;25:1469–77.
Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65:618–30.
Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.
Lee BP, Vittinghoff E, Hsu C, Han H, Therapondos G, Fix OK, et al. Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post‐liver transplant score. Hepatology. 2019;69:1477–87.
Harrell FJ. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.
Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604.
Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453–73.
Forrest EH, Storey N, Sinha R, Atkinson SR, Vergis N, Richardson P, et al. Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther. 2019;50:442–53.
Zuckoff A. “Why won’t my patients do what's good for them?” Motivational interviewing and treatment adherence. Surg Obes Relat Dis. 2012;8:514–21.
Mellinger J, Winder GS, Fernandez ACJH. Measuring the alcohol in alcohol‐related liver disease: choices and challenges for clinical research. Hepatology. 2021;73:1207–12.
Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65:618–30.
Asrani SK, Trotter J, Lake J, Ahmed A, Bonagura A, Cameron A, et al. Meeting Report: The Dallas Consensus Conference on liver transplantation for alcohol associated hepatitis. Liver Transpl 2020;26:127–40.
Winder GS, Fernandez AC, Klevering K, Mellinger JL. Confronting the crisis of comorbid alcohol use disorder and alcohol‐related liver disease with a novel multidisciplinary clinic. Psychosomatics. 2020;61:238–53.
Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr., Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–9.
Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–8.
Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747–56.
Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54:1174–9.